These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 32499442)
61. Cancer in light of experimental evolution. Sprouffske K; Merlo LM; Gerrish PJ; Maley CC; Sniegowski PD Curr Biol; 2012 Sep; 22(17):R762-71. PubMed ID: 22975007 [TBL] [Abstract][Full Text] [Related]
62. Identification of a signature of evolutionarily conserved stress-induced mutagenesis in cancer. Cisneros LH; Vaske C; Bussey KJ Front Genet; 2022; 13():932763. PubMed ID: 36147501 [TBL] [Abstract][Full Text] [Related]
63. Stress-Induced Mutagenesis: Implications in Cancer and Drug Resistance. Fitzgerald DM; Hastings PJ; Rosenberg SM Annu Rev Cancer Biol; 2017 Mar; 1():119-140. PubMed ID: 29399660 [TBL] [Abstract][Full Text] [Related]
64. Non-genetic mechanisms of therapeutic resistance in cancer. Marine JC; Dawson SJ; Dawson MA Nat Rev Cancer; 2020 Dec; 20(12):743-756. PubMed ID: 33033407 [TBL] [Abstract][Full Text] [Related]
65. Chromothripsis drives the evolution of gene amplification in cancer. Shoshani O; Brunner SF; Yaeger R; Ly P; Nechemia-Arbely Y; Kim DH; Fang R; Castillon GA; Yu M; Li JSZ; Sun Y; Ellisman MH; Ren B; Campbell PJ; Cleveland DW Nature; 2021 Mar; 591(7848):137-141. PubMed ID: 33361815 [TBL] [Abstract][Full Text] [Related]
73. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Pastushenko I; Mauri F; Song Y; de Cock F; Meeusen B; Swedlund B; Impens F; Van Haver D; Opitz M; Thery M; Bareche Y; Lapouge G; Vermeersch M; Van Eycke YR; Balsat C; Decaestecker C; Sokolow Y; Hassid S; Perez-Bustillo A; Agreda-Moreno B; Rios-Buceta L; Jaen P; Redondo P; Sieira-Gil R; Millan-Cayetano JF; Sanmatrtin O; D'Haene N; Moers V; Rozzi M; Blondeau J; Lemaire S; Scozzaro S; Janssens V; De Troya M; Dubois C; Pérez-Morga D; Salmon I; Sotiriou C; Helmbacher F; Blanpain C Nature; 2021 Jan; 589(7842):448-455. PubMed ID: 33328637 [TBL] [Abstract][Full Text] [Related]
74. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Russo M; Chen M; Mariella E; Peng H; Rehman SK; Sancho E; Sogari A; Toh TS; Balaban NQ; Batlle E; Bernards R; Garnett MJ; Hangauer M; Leucci E; Marine JC; O'Brien CA; Oren Y; Patton EE; Robert C; Rosenberg SM; Shen S; Bardelli A Nat Rev Cancer; 2024 Oct; 24(10):694-717. PubMed ID: 39223250 [TBL] [Abstract][Full Text] [Related]
75. Applications of single-cell technologies in drug discovery for tumor treatment. Liu B; Hu S; Wang X iScience; 2024 Aug; 27(8):110486. PubMed ID: 39171294 [TBL] [Abstract][Full Text] [Related]
76. Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies. He J; Qiu Z; Fan J; Xie X; Sheng Q; Sui X Signal Transduct Target Ther; 2024 Aug; 9(1):209. PubMed ID: 39138145 [TBL] [Abstract][Full Text] [Related]
77. mTORC2-driven chromatin cGAS mediates chemoresistance through epigenetic reprogramming in colorectal cancer. Lv G; Wang Q; Lin L; Ye Q; Li X; Zhou Q; Kong X; Deng H; You F; Chen H; Wu S; Yuan L Nat Cell Biol; 2024 Sep; 26(9):1585-1596. PubMed ID: 39080411 [TBL] [Abstract][Full Text] [Related]
78. The Potential Links between lncRNAs and Drug Tolerance in Lung Adenocarcinoma. Davis WJH; Drummond CJ; Diermeier S; Reid G Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062685 [TBL] [Abstract][Full Text] [Related]
79. Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins. Trigos AS; Bongiovanni F; Zhang Y; Zethoven M; Tothill R; Pearson R; Papenfuss AT; Goode DL Genome Biol; 2024 Apr; 25(1):110. PubMed ID: 38685127 [TBL] [Abstract][Full Text] [Related]
80. Metabolic Adaptation and Cellular Stress Response As Targets for Cancer Therapy. Lee CJ; Yoon H World J Mens Health; 2024 Jan; 42(1):62-70. PubMed ID: 38171377 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]